Mercury Biopharmaceutical (6932) Stock Overview
Engages in the development of drugs for unmet needs in Taiwan. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
6932 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Mercury Biopharmaceutical Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NT$9.50 |
| 52 Week High | NT$17.45 |
| 52 Week Low | NT$4.95 |
| Beta | -2.78 |
| 1 Month Change | 72.41% |
| 3 Month Change | 6.74% |
| 1 Year Change | -27.76% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -24.90% |
Recent News & Updates
Recent updates
Shareholder Returns
| 6932 | TW Pharmaceuticals | TW Market | |
|---|---|---|---|
| 7D | 3.6% | -1.0% | -1.5% |
| 1Y | -27.8% | 6.5% | 20.1% |
Return vs Industry: 6932 underperformed the TW Pharmaceuticals industry which returned 6.5% over the past year.
Return vs Market: 6932 underperformed the TW Market which returned 20.1% over the past year.
Price Volatility
| 6932 volatility | |
|---|---|
| 6932 Average Weekly Movement | 11.9% |
| Pharmaceuticals Industry Average Movement | 4.4% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in TW Market | 8.6% |
| 10% least volatile stocks in TW Market | 2.0% |
Stable Share Price: 6932's share price has been volatile over the past 3 months compared to the TW market.
Volatility Over Time: 6932's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of TW stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2019 | n/a | Elton Liang | merdury.com |
Mercury Biopharmaceutical Corporation engages in the development of drugs for unmet needs in Taiwan. The company develops StackDose platform, a drug development platform to produce new dosage forms with precise time-controlled dissolution, precise site absorption, and various dosage adjustments to enhance the bio-availability of active pharmaceutical ingredients to reduce the dosage of drugs and its side effects. It develops drugs for treating erectile dysfunction, pulmonary hypertension, sleep disorder, benign prostatic hyperplasia, angina pectoris, migraine, anti-hypertension, and analgesic.
Mercury Biopharmaceutical Corporation Fundamentals Summary
| 6932 fundamental statistics | |
|---|---|
| Market cap | NT$3.98b |
| Earnings (TTM) | -NT$70.59m |
| Revenue (TTM) | NT$246.00k |
Is 6932 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 6932 income statement (TTM) | |
|---|---|
| Revenue | NT$246.00k |
| Cost of Revenue | NT$38.00k |
| Gross Profit | NT$208.00k |
| Other Expenses | NT$70.80m |
| Earnings | -NT$70.59m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.17 |
| Gross Margin | 84.55% |
| Net Profit Margin | -28,696.34% |
| Debt/Equity Ratio | 16.3% |
How did 6932 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/11/18 21:24 |
| End of Day Share Price | 2025/11/18 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Mercury Biopharmaceutical Corporation is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.